Please login to the form below

Not currently logged in
Email:
Password:

Dermavant’s Vtama shows promise in paediatric atopic dermatitis trial

The trial included children aged between two to 17 years and the treatment was well tolerated

HQ

Dermavant Sciences (Dermavant) has shared positive results from its paediatric maximal usage study of Vtama (tapinarof) cream, in children aged from two to 17 years old with atopic dermatitis (AD).

The open-label trial enrolled 36 patients between the ages of two to 17 years and showed that Vtama offers favourable safety and clinical improvement for children in this age group with AD. There was a low incidence of adverse events and, even when applied to areas of sensitive skin, Vtama was well tolerated.

The study used the same dose and frequency as Dermavant’s ongoing ADORING 1 and ADORING 2 pivotal trials for AD. In May, the US Food and Drug Administration (FDA) approved Vtama at same dose and frequency to treat adults with plaque psoriasis.

The data will be added to Dermavant’s expected supplemental new drug application for AD, which will also include results from the company’s ongoing ADORING 1, 2, and 3 phase 3 studies for those aged two years and older.

AD, more commonly known as eczema, is one of the most common inflammatory skin diseases, and occurs most frequently in children, affecting up to 30% globally.

Philip Brown, chief medical officer of Dermavant, said: “We are delighted with the results from our maximal usage study of VTAMA cream, 1% in AD, which for the first time demonstrated highly favourable safety, pharmacokinetics, and clinical improvement in paediatric patients as young as two years of age.

“Despite maximal use conditions, in patients with up to 90% body surface area affected, we observed minimal to no systemic exposure, a low incidence of adverse events and an overall excellent safety profile. In addition, these encouraging results were demonstrated in spite of the skin barrier defect common in AD patients.”

Dermavant expects to announce the top-line results from ADORING 1 and ADORING 2 in the first half of 2023.

Article by
Fleur Jeffries

9th November 2022

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...